Abstracts tagged "Lupus nephritis"

Abstract Number: 0047 • ACR Convergence 2025
Monocyte Transcriptomic Signatures Uncover Potential Pathogenic Mechanisms of the APOL1 High Risk Genotype (HRG)
Vishnuprabu Pandian¹, Adebola Agboola¹, Sivasubramanian ramani², Christele Felix³, Andrra Nimoni³, Jasmin Divers⁴, Timothy Niewold⁵ and Ashira Blazer², ¹University of Maryland, Baltimore, Baltimore, Maryland, ²University of Maryland Baltimore, Baltimore, Maryland, ³Hospital for Special Surgery, New York, NY, ⁴NYU Grossman Long Island School of Medicine, New York, New York, ⁵Hospital for Special Surgery, New York, New York
Background/Purpose: Compared to the low-risk genotype (LRG) the APOL1 high-risk genotype (HRG) confers an increased risk of end stage kidney disease among individuals with systemic…
Abstract Number: 0615 • ACR Convergence 2025
Systemic Lupus Erythematosus Flares in Patients with End-Stage Kidney Disease on Renal Replacement Therapy or after Transplant
Jacob Klein¹, Judith Lin¹ and Marilly Palettas², ¹Ohio State University Wexner Medical Center, Columbus, OH, ²Center for Biostatistics Ohio State University, Columbus, OH
Background/Purpose: It has been observed that systemic lupus erythematosus (SLE) activity often goes into remission in patients with end-stage kidney disease (ESKD) on dialysis or…
Abstract Number: 0906 • ACR Convergence 2025
Preclinical Characterization of IBI3034, an TACI and BCMA Chimeric Fc Fusion Protein, that Potently Modulates B Lymphocytes and Serum Immunoglobulin for the Treatment of B cell Related Autoimmune Disease
Yao Xiong, Shuaixiang Zhou, Zhimin Zhang, Bin Li, Zhihao Ming, Yuyu Wu, Liu Li, Chang Li, Fenggen Fu, Zhihai Wu, Shun Wang, Guogang Yuan, Yuling Song, Jinyang Li, Huizhong Xiong and Bingliang Chen, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: Dysregulated B-cell activation plays a pivotal role in the pathogenesis of various autoimmune diseases. B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are…
Abstract Number: 1480 • ACR Convergence 2025
Urinary Biomarkers Detect Proliferative Lupus Nephritis in SLE Patients with Subclinical Proteinuria.
CHEN-YU LEE¹, Rufei Lu², Carla Guthridge², Wade DeJager³, Jennifer Barnas⁴, Jennifer Anolik⁵, H Michael Belmont⁶, Judith James², Jill Buyon⁷, Brad Rovin⁸, Michelle Petri⁹, Joel Guthridge² and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴University of Rochester, Rochester, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶NYU School of Medicine, New York, NY, ⁷NYU Grossman School of Medicine, New York, NY, ⁸The Ohio State University, Columbus, OH, ⁹Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Early treatment is critical to prevent irreversible kidney damage in lupus nephritis (LN). Current guidelines recommend kidney biopsy when the urine protein-to-creatinine ratio (UPCR)…
Abstract Number: 1721 • ACR Convergence 2025
Excess Mortality in SLE Is Concentrated in Lupus Nephritis and aPL-Positive Subsets: A population-based inception cohort study
Mario Bautista-Vargas¹, Erika Navarro-Mendoza¹, Jaime Flores-Gouyonnet¹, Ali Ardekani¹, Maria Cuellar-Gutierrez¹, Gabriel Figueroa-Parra², Mariana Gonzalez-Treviño³, Jose Antonio Meade-Aguilar⁴, Alain Sanchez-Rodriguez⁵, Andrew C. Hanson¹, Cassondra Hulshizer⁶, Cynthia Crowson⁷ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Boston University/Boston Medical Center, Boston, MA, ⁵ABC Medical Center, Ciudad de México, Federal District, Mexico, ⁶Mayo Clinic, Rochester, ⁷Mayo Clinic, Stewartvillle, MN
Background/Purpose: Five-year survival in SLE has plateaued since the 1990s. Most epidemiologic studies pool all SLE phenotypes; It is possible that the excess mortality observed…
Abstract Number: 2399 • ACR Convergence 2025
Identification of an LN endotype linked to intestinal expansion of Pathogenic Strains of a Pathobiont Bacterium that induces Systemic Thrombo-inflammatory Pathways directly measurable in Urine
Gregg Silverman¹, Abhimanyu Amarnani², Zakia Azad² and Brad Rovin³, ¹NYU Grossman School of Medicine, New York, NY, ²New York University Grossman School of Medicine, New York, NY, ³The Ohio State University, Columbus, OH
Background/Purpose: During disease, ~50% of SLE patients develop lupus nephritis (LN), one of the most serious complication. Despite the best therapy, within 15 years, ~20%…
Abstract Number: 2468 • ACR Convergence 2025
RESET-SLE: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Non-Renal SLE and Lupus Nephritis
Saira Sheikh¹, Vimal Derebail¹, Natalie Grovner¹, Gaurav Gulati², Mehrdad Abedi³, Meghan Sise⁴, Matthew Frigault⁴, Christopher Palma⁵, Patrick Reagan⁵, Cuoghi Edens⁶, Satya Kosuri⁶, Caitlin Elgarten⁷, Jon Burnham⁸, Jonathan Hogan⁹, Yvonne White⁹, Carl diCasoli⁹, Rebecca Estremera⁹, Jenell Volkov⁹, Daniel Nunez⁹, Fatemeh Hadi-Nezhad¹⁰, Thomas Furmanak⁹, Jason Stadanlick⁹, Larissa Ishikawa⁹, Zachary Vorndran⁹, Alexandra Ellis⁹, Jazmean Williams⁹, Steve Flanagan⁹, Quynh Lam¹⁰, Samik Basu⁹, Raj Tummala¹⁰ and David Chang⁹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of California, Davis School of Medicine, Davis, CA, ³University of California, Davis School of Medicine, Davis, ⁴Massachusetts General Hospital, Boston, MA, ⁵University of Rochester, Rochester, NY, ⁶University of Chicago, Chicago, IL, ⁷Children's Hospital of Philadelphia, Philadelphia, PA, ⁸Children's Hospital of Philadelphia, Bryn Mawr, PA, ⁹Cabaletta Bio, Philadelphia, PA, ¹⁰Cabaletta Bio, Philadelphia
Background/Purpose: Current goals of treatment for systemic lupus erythematosus (SLE) are to achieve low disease state/remission, prevent flares, minimize organ damage, and decrease long-term morbidity…
Abstract Number: 0136 • ACR Convergence 2025
Beyond Thrombosis: Histological Spectrum, Predictors and Outcomes of Renal Involvement in Primary Antiphospholipid Syndrome: A Single-Centre Cohort Study
RITESH KUMAR MISHRA¹, SUBIN PHILIP², RIZWANA NAUSHAD², AISHWARYA GOPAL³, Chengappa Kavadichanda², CHRISTINA MARIASELVAM², RAJESH N G², Molly mary Thabah³ and VIR SINGH NEGI², ¹JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, Bhubaneswar, India, ²JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, Puducherry, India, ³JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, India
Background/Purpose: Renal involvement in primary APS is underrecognized and histologically diverse, encompassing both vascular and glomerular pathology. We aimed to describe the histopathology, outcomes of…
Abstract Number: 0618 • ACR Convergence 2025
Therapeutic landscape of systemic lupus erythematosus pure membranous nephropathy: a nationwide population-based study
Kevin Chevalier¹, Romain Brousse², alexandre karras³, Nathalie Costedoat-Chalumeau⁴, Julien Dang⁵, Maxence Taillar⁶, Noémie JOURDE-CHICHE⁶, Charles Ronsin⁷, Moglie Le Quintrec-Donnette⁸, Marie Julien⁹, Antoine Huart¹⁰, Aymeric Couturier¹¹, Pierre Pommerolle¹², Céline Lebas¹³, Antoine Coussement¹⁴, Marion Chapal¹⁵, Christophe Barba¹⁶, Alexia Gauffre¹⁷, Maxime Teisseyre¹⁸, Johan Noble¹⁹, Chloé Comarmond²⁰, Eve Vilaine²¹, Jean-François Augusto²², Aurélie Hummel²³, Evangeline Pillebout²⁴, Jean-Michel Halami²⁵, Olivier Moranne²⁶, Eric Daugas²⁷, Jean-Jacques Boffa² and Emmanuel Esteve², ¹Université Paris Cité, Montrouge, France, ²Tenon hospital, Paris, France, ³HEGP - assistance publique hopitaux de paris, paris, France, ⁴Cochin hospital, Paris, France, ⁵Bicêtre hospital, Kremlin Bicêtre, France, ⁶Centre de Néphrologie et Transplantation Rénale, Hôpital de la Conception, Assistance Publique-Hôpitaux de Marseille, Marseille, France., Marseille, France, ⁷Department of Nephrology and Immunology, Nantes University Hospital, Nantes, France., Nantes, France, ⁸Service de Néphrologie-Soins Intensifs-Dialyse et Transplantation, Hôpital Lapeyronie, Montpellier, France., Montpellier, France, ⁹Service de néphrologie, CHU de la Réunion, Saint-Denis, France., Saint-Denis, France, ¹⁰Département de Néphrologie et Transplantation d’Organes, Axe Transplantation – Immunité – Environnement, CHU de Toulouse, France, Toulouse, France, ¹¹Nephrology Unit, American Hospital of Paris, Neuilly-sur-Seine, France, Neuilly-sur-seine, France, ¹²Department of Nephrology, Dialysis, and Transplantation, University of Picardie Jules Verne, Amiens University Hospital, Amiens, France., Amiens, France, ¹³Service de Néphrologie et Transplantation rénale, Centre Hospitalier Régional Universitaire de Lille, Lille, France., Lille, France, ¹⁴Service de Néphrologie, CHU de Dijon, Dijon, France., Dijon, France, ¹⁵Departement of Nephrology, Hospital of Vendée, La Roche-Sur-Yon, ⁸⁵⁰⁰⁰, France., La Roche-sur-yon, France, ¹⁶Department of Nephrology and Nutrition, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre- Bénite, France, Lyon, France, ¹⁷Service de néphrologie, CHU de Rouen, Rouen, France, Rouen, France, ¹⁸Département de Néphrologie, Dialyse et Transplantation, CHU de Nice, Université Côte d'Azur, France., Nice, France, ¹⁹Department of Nephrology, Grenoble-Alpes University Hospital, Grenoble, France., Grenoble, France, ²⁰Internal Medicine Department, Département Médico-Universitaire INVICTUS, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris (APHP).Nord-Université Paris-Cité, ⁷⁵⁰¹⁰ Paris, France., Paris, France, ²¹Ambroise Paré hospital, Boulogne, France, ²²Service de Néphrologie-Dialyse-Transplantation, Université d'Angers, CHU Angers, Angers, France., Angers, France, ²³Department of Nephrology, Necker-Enfants Malades Hospital, APHP, Paris, France., Paris, France, ²⁴Nephrology Unit, Saint Louis Hospital, Paris, France., Paris, France, ²⁵Department of Nephrology, UMR¹³²⁷ ischemia, INI-CRCT, Tours University Hospital, Tours University, Tours, France., Tours, France, ²⁶Service de Néphrologie, dialyse et aphérèse, CHU de Nîmes, IDESP Universite de Montpellier, France, Montpellier, France, ²⁷Department of Nephrology, Hospital Bichat - Claude-Bernard, Paris, France
Background/Purpose: Renal involvement is a major prognostic factor in systemic lupus erythematosus. Pure lupus membranous nephropathy (PLMN, class V) represents 5–20% of lupus nephritis cases,…
Abstract Number: 0913 • ACR Convergence 2025
Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
Veronica Campbell¹, Yi Zhang¹, Virginia Massa¹, Jordan Leedberg¹, Erik Corcoran¹, Emily Lurier¹, Ryan Camire², Chris Carroll¹, Chris Ho¹, Dapeng Chen¹, Bradley Enerson¹, Revonda Mehovic¹, Ziyan Zhao¹, Lincoln Howarth¹, Susanne Breitkopf¹, Sarah Martinez¹, Melissa Ford¹, Xue Fei¹, Murugappan Sathappa¹, Juliet Williams³, Matthew Weiss³, Arsalan Shabbir³ and Nello Mainolfi⁴, ¹Kymera Therapeutics, Watertown, MA ⁰²⁴⁷², ²Kymera Therapeutics, Watertown, MA ⁰²⁴⁷², MA, ³Kymera Therapeutics, Watertown, ⁴Kymera Therapeutics, Watertown, MA
Background/Purpose: IRF5 is a transcription factor and regulator of immune responses activated downstream of pattern recognition receptors, in particular endosomal toll-like receptors (TLR), TLR7, TLR8…
Abstract Number: 1485 • ACR Convergence 2025
Lupus Under the Lens: Fibrinogen-to-Albumin Ratio as a Novel Inflammatory Index
guru Vijay Chagalakondu and Vijaya prasanna Parimi, ESIC Medical College and Super Specilaity Hospital, hyderabad, Telangana, India
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune condition presenting with unpredictable varying levels of severity. Thus, constant monitoring of disease activity is…
Abstract Number: 1763 • ACR Convergence 2025
Spatial Organization and Function of Disease-Associated Macrophages in Lupus Nephritis: Insights from Cross-Species Analyses
Paul Hoover¹, Chirag Raparia², Rollin Leavitt³, Nir Hacohen⁴, Arnon Arazi⁵ and Anne Davidson², ¹Brigham and Women's Hospital, Boston, MA, ²Feinstein Institutes for Medical Research, Manhasset, NY, ³Broad Institute, Boston, MA, ⁴Broad Institute, Cambridge, MA, ⁵The Feinstein Institutes for Medical Research, Manhasset
Background/Purpose: Myeloid cells are linked to kidney injury in lupus nephritis (LN) but lack targeted therapies, underscoring the need to better understand myeloid biology in…
Abstract Number: 2401 • ACR Convergence 2025
Associations between Serum Levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Activity and Chronicity Features in Diagnostic and Per-Protocol Repeat Kidney Biopsies in Patients with Lupus Nephritis
Sandra Jagerback¹, Frederic Houssiau², Dionysis Nikolopoulos³, Lina Wirestram⁴, Julius Lindblom⁵, Farah Tamirou⁶, Christopher Sjowall⁷ and Ioannis Parodis⁸, ¹Karolinska Institutet, Stockhom, Stockholms Lan, Sweden, ²CUSL, BRUSSELS, Belgium, ³Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁴Linköping University, Linköping, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Cliniques universitaires Saint-Luc, Brussels, Belgium, ⁷Linkoping University, Linkoping, Sweden, ⁸Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden
Background/Purpose: Serum levels of soluble urokinase plasminogen activator receptor (suPAR) have been associated with organ damage accumulation in patients with recent-onset systemic lupus erythematosus (SLE).…
Abstract Number: 2600 • ACR Convergence 2025
Deconstructing Lupus Nephritis Kidney Tissue at Single-Cell Resolution
Nicholas Sugiarto¹, Michelle Curtis², Siddarth Gurajala², Thomas Eisenhaure³, Qian Xiao⁴, Joseph Mears⁵, Arnon Arazi⁶, Paul Hoover⁷, Celine Berthier⁸, Saori Sakaue⁹, Andrea Fava¹⁰, David Hildeman¹¹, E. Steve Woodle¹², Brad Rovin¹³, Jennifer Barnas¹⁴, Maria Dall'Era¹⁵, Chaim Putterman¹⁶, Diane Kamen¹⁷, Maureen McMahon¹⁸, Jennifer Grossman¹⁹, Kenneth Kalunian²⁰, Jeffrey Hodgin²¹, Fernanda Payan Schober²², Mariko Ishimori²³, Michael Weisman²³, William Apruzzese²⁴, Joel Guthridge²⁵, Michael Brenner²⁶, Jennifer Anolik²⁷, David Wofsy²⁸, Judith James²⁵, Deepak Rao⁷, Anne Davidson²⁹, Michelle Petri³⁰, Jill Buyon³¹, Nir Hacohen³², Betty Diamond³³ and Soumya Raychaudhuri⁷, ¹Harvard Medical School, Brookline, MA, ²Harvard Medical School, Boston, ³Broad Institute, Cambridge, MA, ⁴Harvard Medical School, Boston, MA, ⁵Michigan University, Ann Arbor, MI, ⁶Feinstein Institutes for Medical Research, Acton, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸University of Michigan, Ann Arbor, MI, ⁹University of Washington, Yokohama, Japan, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Cincinnati Children's Hospital, Cincinnati, OH, ¹²UC Health, Cincinnati, ¹³The Ohio State University, Columbus, OH, ¹⁴University of Rochester, Rochester, NY, ¹⁵Division of Rheumatology, University of California, San Francisco, CA, ¹⁶Albert Einstein College of Medicine, Safed, Israel, ¹⁷Medical University of South Carolina, Johns Island, SC, ¹⁸UCLA David Geffen School of Medicine, Los Angeles, CA, ¹⁹UCLA, Sherman Oaks, CA, ²⁰UC San Diego, La Jolla, CA, ²¹University of Michigan, Ann Arbor, ²²TTUHSC, El Paso, TX, ²³Cedars-Sinai Medical Center, Los Angeles, CA, ²⁴Pfizer, Boston, ²⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁶Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ²⁷University of Rochester Medical Center, Rochester, NY, ²⁸University of California San Francisco, SF, CA, ²⁹Feinstein Institutes for Medical Research, Manhasset, NY, ³⁰Johns Hopkins University School of Medicine, Timonium, MD, ³¹NYU Grossman School of Medicine, New York, NY, ³²Broad Institute of MIT Harvard, Cambridge, MA, ³³The Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Lupus nephritis (LN) is a heterogeneous disease driven by diverse immune and tissue cell types. We defined the cell states in the tissue and…
Abstract Number: 0373 • ACR Convergence 2025
Implementation of a Lupus Self-Management mHealth App: Using Incentives to Drive Engagement
Melissa French¹, Katherine Carpenter², Eric Johnson², Melicent Miller² and Mary Crimmings², ¹Lupus Foundation of America, Alexandria, VA, ²Lupus Foundation of America, Washington, DC
Background/Purpose: As part of a five-year cooperative agreement with the Centers for Disease Control and Prevention, the Lupus Foundation of America (LFA) has implemented the…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].